State of the Art. Short-course chemotherapy for pulmonary tuberculosis, Am Rev Respir Dis, vol.111, pp.325-353, 1975. ,
URL : https://hal.archives-ouvertes.fr/hal-02625816
Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units, 1946-1986, with relevant subsequent publications, Int J Tuberc Lung Dis, vol.3, pp.231-279, 1999. ,
Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies, Lancet Infect Dis, vol.18, pp.183-98, 2018. ,
, New York: The Working Group for New TB Drugs; c2016
Driving the Way to Tuberculosis Elimination: The Essential Role of Fundamental Research, Clin Infect Dis, vol.63, issue.3, pp.370-375, 2016. ,
Advances in clinical trial design for development of new TB treatments: A call for innovation, PLoS Med, vol.16, issue.3, p.1002769, 2019. ,
URL : https://hal.archives-ouvertes.fr/inserm-02170758
, Global investments in Tuberculosis research and development: past, present, and future. Proceedings of the First WHO global ministerial conference on ending tuberculosis in the sustainable development era: a multisectoral response, pp.16-17, 2017.
World Health Organization: Geneva, 2017. ,
, Report of the Technical Consultation on Advances in Clinical Trial Design for Development of New TB Treatments, Geneva: World Health Organization, vol.17, 2018.
Bactericidal mechanisms in short-course chemotherapy, Bull Int Union Tuberc, vol.53, pp.254-259, 1978. ,
Role of individual drugs in the chemotherapy of tuberculosis, Int J Tuberc Lung Dis, vol.4, issue.9, pp.796-806, 2000. ,
Microbial persistence, Yale J Biol Med, vol.30, pp.257-291, 1958. ,
Targeting persisters for tuberculosis control, Antimicrob Agents Chemoth, vol.5, pp.2223-2230, 2012. ,
TB drug development: immunology at the table, Immunol Rev, vol.264, pp.308-326, 2015. ,
Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis, AJRCCM, vol.170, p.10, 2004. ,
Mthiyane T, and the Gatifloxacin for TB (OFLOTUB) study team. A phase II study of the sterilizing activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis, Int J Tuberc Lung Dis, vol.12, issue.2, pp.128-138, 2008. ,
Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial, Lancet, vol.373, pp.1183-1189, 2009. ,
A Patient-Level Pooled Analysis of Treatment Shortening Regimens for Drug-Susceptible Pulmonary Tuberculosis, Nature Med, vol.24, issue.11, p.30397355, 2018. ,
Pharmacokinetic-pharmacodynamic modeling of antibacterial drugs, Pharmacol Rev, vol.65, pp.1053-1090, 2013. ,
The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells, Nat Rev Microbiol, vol.12, issue.3, pp.159-67, 2014. ,
The association between sterilizing activity and drug distribution into tuberculosis lesions, Nat Med, vol.21, issue.10, pp.1223-1230, 2015. ,
Role of individual drugs in the chemotherapy of tuberculosis, Int J Tuberc Lung Dis, vol.4, issue.9, pp.796-806, 2000. ,
Tuberculosis drugs' distribution and emergence of resistance in patient's lung lesions: A mechanistic model and tool for regimen and dose optimization, PLoS Med, vol.16, issue.4, 2019. ,
Artificial intelligence enabled parabolic response surface platform identifies ultra-rapid near-universal TB drug treatment regimens comprising approved drugs, PLoS ONE, vol.14, issue.5, p.217670, 2019. ,
New Paradigm for Translational Modeling to Predict Long-term Tuberculosis Treatment Response, Clin Transl Sci, vol.10, issue.5, pp.366-379, 2017. ,
The role of surrogate markers in the clinical evaluation of antituberculous chemotherapy, Curr Med Chem-Anti-Infective Agents, vol.4, issue.4, pp.1-8, 2005. ,
Advancing the development of new tuberculosis treatment regimens: The essential role of translational and clinical pharmacology and microbiology ,
, PLoS Med, vol.16, issue.7, p.1002842, 2019.
Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations from two phase II clinical trials, Clin Pharmacol Ther, vol.102, issue.2, pp.321-331, 2017. ,
The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis, Clin Infect Dis, vol.67, issue.1, pp.34-41, 2018. ,
Challenges in tuberculosis drug research and development, Nat Med, vol.13, issue.3, pp.290-294, 2007. ,
Keeping phase III tuberculosis trials relevant: Adapting to a rapidly changing landscape, PLoS Med, vol.16, issue.3, p.1002767, 2019. ,
URL : https://hal.archives-ouvertes.fr/inserm-02170885
Designing noninferiority tuberculosis treatment trials: Identifying practical advantages for drug regimens with acceptable effectiveness, PLoS Med, vol.16, issue.7, p.1002850, 2019. ,
A Simulation Study Evaluating Bio-Creep Risk in Serial Noninferiority Clinical Trials for Preservation of Effect, Stat Biopharm Res, vol.7, issue.1, pp.12-24, 2015. ,
A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis, N Engl J Med, vol.380, pp.1201-1213, 2019. ,
Innovative trial designs are practical solutions for improving the treatment of tuberculosis, J Infect Dis, vol.205, issue.2, pp.250-257, 2012. ,
A Bayesian response-adaptive trial in tuberculosis: The endTB trial, Clin Trials, vol.14, pp.17-28, 2017. ,
Adherence interventions and outcomes of tuberculosis treatment: A systematic review and meta-analysis of trials and observational studies, PLoS Med, vol.15, issue.7, 2018. ,
The importance of adherence in tuberculosis treatment clinical trials and its relevance in explanatory and pragmatic trials, PLoS Med, vol.16, issue.12, p.1002884, 2019. ,
, Influence of Adherence to Treatment and Response of Cholesterol on Mortality in the Coronary Drug Project, N Engl J Med, vol.303, issue.18, pp.1038-1041, 1980.
Pragmatic Trials, N Engl J Med, vol.375, pp.454-63, 2016. ,
Effectiveness of the direct observation component of DOTS for tuberculosis: a randomised controlled trial in Pakistan, Lancet, vol.357, pp.664-669, 2001. ,
Family-member DOTS and community DOTS for tuberculosis control in Nepal: cluster-randomised controlled trial, Lancet, vol.367, pp.903-909, 2006. ,
Improving adherence to tuberculosis treatment in a resource-poor setting: A Cluster Randomised Controlled Trial, JAMA, vol.297, issue.4, pp.380-386, 2007. ,
Inclusion of key populations in clinical trials of new antituberculosis treatments: Current barriers and recommendations for pregnant and lactating women, children, and HIV-infected persons, PLoS Med, vol.16, issue.8, p.1002882, 2019. ,
A Community Perspective on the Inclusion of Pregnant Women in Tuberculosis Drug Trials, Clin Infect Dis, vol.65, issue.8, pp.1383-1387, 2017. ,
Tuberculosis in pregnant and postpartum women: epidemiology, management, and research gaps, Clin Infect Dis, vol.55, issue.11, pp.1532-1549, 2012. ,
Toward Earlier Inclusion of Pregnant and Postpartum Women in Tuberculosis Drug Trials: Consensus statements from an international expert panel, Clin Infect Dis, vol.62, issue.6, pp.761-769, 2016. ,
Towards early inclusion of children in tuberculosis drugs trials: a consensus statement, Lancet Infect Dis, vol.15, issue.6, p.25957923, 2015. ,
State-of-the-Art Review of HIV-TB Coinfection in Special Populations, Clin Pharmacol Ther, vol.104, issue.6, pp.1098-1109, 2018. ,
Challenges of TB and HIV co-treatment: updates and insights, Curr Opin HIV AIDS, vol.13, issue.6, pp.486-491, 2018. ,
, New York: The Working Group for New TB Drugs; c2016, The Working Group for New TB Drugs, 2019.
, US Food and Drug Administration
Randomised controlled trials for Ebola: practical and ethical issues, Lancet, vol.18, issue.9952, pp.61734-61741, 2014. ,
Development of new TB regimens: Harmonizing trial design, product registration requirements, and public health guidance, PLoS Med, vol.16, issue.9, p.1002915, 2019. ,
URL : https://hal.archives-ouvertes.fr/inserm-02430787
Advances in clinical trial design for development of new TB treatments-Translating international tuberculosis treatment guidelines into national strategic plans: Experiences from Belarus, South Africa, and Vietnam, PLoS Med, vol.16, issue.10, p.1002896, 2019. ,
, End TB Strategy: global strategy and targets for tuberculosis prevention, care, and control after, 2014.
, Global Investments in Tuberculosis Research and Development: Past, Present, and Future